- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01273272
Cognitive-Behavioral Treatment for Mild Alzheimer's Patients and Their Caregivers (CBTAC)
Cognitive-Behavioral Treatment for Patients With Mild Alzheimer's Dementia: A Randomized Controlled Trial
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Mild Alzheimer's dementia (AD) cases are with 15 millions worldwide the largest fraction of all AD cases. Most patients are cared for by their family at home. Neuropsychiatric symptoms are very common in AD, even as early as in mild AD: About 90% of all mild AD cases experience neuropsychiatric symptoms, most frequently depression, anxiety, and irritability. These symptoms are associated with greater morbidity, reduced quality of life for the patient, increased burden and depression for the caregiver, higher costs of care, and nursing home placement. Thus, interventions aimed at treating these symptoms could have a tremendous effect on pa-tients, caregivers, and society.
This study is a randomized, controlled trial (RCT) evaluating a comprehensive CBT-based, multi-component treatment programme consisting of eight modules (diagnosis and goal-setting; psycho-education; engagement in pleasant activities; cognitive restructuring; life review; training caregiver in behavior management techniques; interventions for the caregiver; couples counseling) and 20 sessions.
This trial aims at significantly reducing depressive and other neuropsychiatric symptoms in the AD patients, and secondary in reducing burden and depressive symptoms of the caregivers. Patients with AD alone or mixed AD and vascular dementia that are in the mild stage and suffer under any neuropsychiatric symptom will be included. The patients and their caregiver will be randomized to either the CBT-based intervention or to the control condition that receives treatment as usual (TAU).
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
-
Zurich, Suíça, 8032
- Psychiatric University Hospital, Clinic for Geriatric Medicine
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Patients have to meet NINCDS-ADRDA criteria for probable or possible AD (McKhann et al., 1984). Mixed Alzheimer and Vascular dementia cases will also be included.
- Only AD cases with a mild dementia severity will be included, determined by the Clinical Dementia Rating (CDR) scale (i.e. scores of 0.5 or 1, Morris, 1993) and by the Mini Mental State Examination (MMSE) (i.e. scores of 20 or more, Folstein, Folstein, & McHugh, 1975).
- The patient must suffer under any non-cognitive symptom that motivates him to accept psy-chotherapeutic help.
- A caregiver must be available to take part in most of the therapy sessions.
Exclusion Criteria:
- concomitant alcohol or drug addiction and a history of a malignant disease, severe organ failure, metabolic or hematologic disorders, neurosurgery or neurological condition such as Parkinson's disease, epilepsy, postencephalitic and postconcussional syndrome
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Cognitive Behavioral Therapy (CBT)
Comprehensive, CBT-based, multi-component treatment.
Comprehensive CBT intervention in addition to standard treatment
|
It includes eight modules: diagnosis and goal setting; psychoeducation; engagement in pleasant activities; cognitive restructuring; live review; training caregiver in behavior man-agement techniques; interventions for the caregiver; and couples counselling.
It consists of 20 weekly sessions (plus appr.
5 single session with caregiver).
Outros nomes:
|
Comparador Ativo: Treatment as usual (TAU)
Standard Treatment (medical and psychosocial)
|
Each patient/caregiver must receive at least three out of six interventions: (1) psychoeducation on dementia and treatment of dementia (oral and written); (2) appropriate medical treatment; (3) social counseling by specialized staff; (4) memory training in group setting; (5) self-help group for the patient; (6) self-help group for the caregiver.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
---|---|
Change from baseline in Geriatric Depression Scale (GDS)
Prazo: Pre-treatment, posttreatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
|
Pre-treatment, posttreatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
---|---|
Change from baseline in Neuropsychiatric Inventory (NPI)
Prazo: Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
|
Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
|
Change from baseline in Bayer-Activities of Daily Living (B-ADL)
Prazo: Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
|
Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
|
Change from baseline in Stress Coping Inventory (SCI)
Prazo: Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
|
Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
|
Change from baseline in Apathy Evaluation Scale (AES)
Prazo: Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
|
Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
|
Caregiver: Change from baseline in Center for Epidemiologic Studies Depression Scale (CES-D)
Prazo: Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
|
Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
|
Caregiver: Change from baseline in Trait scale of the State Trait Anxiety Inventory (STAI)
Prazo: Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
|
Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
|
Caregiver: Change from baseline in Anger-in and anger-out scales of the State Trait Anger Expression Inventory (STAXI)
Prazo: Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
|
Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
|
Caregiver: Change from baseline in Short-Form Health Survey (SF-12)
Prazo: Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
|
Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
|
Caregiver: Change from baseline in Zarit Burden Interview (ZBI)
Prazo: Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
|
Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
|
Caregiver: Change from baseline in Stress Coping Inventory (SCI)
Prazo: Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
|
Pre-treatment, post-treatment (expected average of 9 months after protreatment), 6- and 12-months follow-up
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Simon Forstmeier, Ph.D., University of Zurich
- Cadeira de estudo: Andreas Maercker, M.D.,Ph.D., University of Zurich
- Cadeira de estudo: Egemen Savaskan, M.D., Psychiatric University Hospital, Zurich
- Cadeira de estudo: Tanja Roth, Ph.D., Psychiatric University Hospital, Zurich
Publicações e links úteis
Publicações Gerais
- Forstmeier S, Maercker A. Problems of aging. Psychotherapy in older age [German]. Göttingen, Germany: Hogrefe. 2008.
- Forstmeier S, Maercker A. Psychotherapie im Alter. Psychotherapeutenjournal 4: 340-352, 2007
- Forstmeier S, Maercker A, Savaskan E, Roth T. Cognitive behavioural treatment for mild Alzheimer's patients and their caregivers (CBTAC): study protocol for a randomized controlled trial. Trials. 2015 Nov 17;16:526. doi: 10.1186/s13063-015-1043-0.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 10-130034/1a
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Doença de Alzheimer
-
ProgenaBiomeRecrutamentoUm estudo piloto não intervencional para explorar o papel da flora intestinal na doença de AlzheimerDoença de Alzheimer | Doença de Alzheimer de início precoce | Doença de Alzheimer de início tardio | Doença de Alzheimer 1 | Doença de Alzheimer 2 | Doença de Alzheimer 3 | Doença de Alzheimer 4 | Doença de Alzheimer 7 | Doença de Alzheimer 17 | Doença de Alzheimer 5 | Doença de Alzheimer 6 | Doença de Alzheimer... e outras condiçõesEstados Unidos
-
Cognito Therapeutics, Inc.RecrutamentoComprometimento Cognitivo | Demência | Doença de Alzheimer | Comprometimento cognitivo leve | Declínio Cognitivo | Doença de Alzheimer de início precoce | Doença de Alzheimer de início tardio | MCI | Demência Alzheimers | Demência leve | Demência do Tipo Alzheimer | Comprometimento Cognitivo, Leve | Doença de Alzheimer... e outras condiçõesEstados Unidos
-
Centre Hospitalier Universitaire de NiceConcluídoPaciente de Alzheimer Predencial | Paciente com Demência de Alzheimer | TestemunhaFrança
-
AphiosAinda não está recrutandoDemência | Doença de Alzheimer 1 | Doença de Alzheimer 2 | Doença de Alzheimer 3
-
Massachusetts Institute of TechnologyRecrutamentoDoença de Alzheimer | Doença de Alzheimer de início precoce | Doença de Alzheimer de início tardio | Doença de Alzheimer | Doença de Alzheimer (incluindo subtipos) | AlzheimerEstados Unidos
-
Novoic LimitedRecrutamentoDoença de Alzheimer | Comprometimento cognitivo leve | Doença de Alzheimer Prodrômica | Doença de Alzheimer (incluindo subtipos) | Doença de Alzheimer pré-clínicaEstados Unidos
-
Novoic LimitedRecrutamentoDoença de Alzheimer | Comprometimento cognitivo leve | Doença de Alzheimer Prodrômica | Doença de Alzheimer (incluindo subtipos) | Doença de Alzheimer pré-clínicaReino Unido
-
Novoic LimitedConcluídoDoença de Alzheimer | Comprometimento cognitivo leve | Doença de Alzheimer Prodrômica | Doença de Alzheimer (incluindo subtipos) | Doença de Alzheimer pré-clínicaEstados Unidos
-
Istanbul University - Cerrahpasa (IUC)Ainda não está recrutandoDemência, tipo Alzheimer | Doença de Alzheimer | Demência de AlzheimerPeru
-
Whanin Pharmaceutical CompanyConcluídoDemência tipo AlzheimerRepublica da Coréia